GSTM1 and anemia: The term ‘uncontrolled’ was not defined in the NICE scope [13]; however, at baseline, patients enrolled in the PEGASUS trial had Hb levels < 10.5 g/dL and the company appeared to assume that these patients could be considered to have anaemia that was uncontrolled.